Keep an eye on gene-editing stocks, like CRISPR Therapeutics (CRSP).
While the stock has already pushed aggressively higher after a US FDA advisory committee gave its sickle cell treatment the green light. Now, as we wait on a final decision from the US FDA in early December, the CRSP stock could move even higher on anticipatory momentum.
Granted, a good deal of positive news has been priced into the stock. However, I still see further upside based on the potential revenue. For example, as noted by Seeking Alpha, “The companies believe the addressable patient pool for exa-cel treatment will number ~20,000. If we multiply that by $2m, the mooted list price, we have a market opportunity of $40bn, and if we multiply that by 40%, CRISPR Therapeutics’ share of revenues, we get to $16bn.”